Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X:
“Big moves in Lung Cancer at ASCO25!
ADCs, KRASG12Ci and TKIs!
NeoADAURA: Neoadjuvant Osimertinib in EGFRm
CheckMate 816 OS update
Tarlatamab reshaping 2L SCLC
Biomarkers, ctDNA, CAR-T, BiTEs!
Excited for ASCO25″
Abner Antonio Murray, Hematology-Oncology Fellow at University of Miami, shared Aakash Desai’s post, adding:
“The depth of science at ASCO25 in lung cancer is next level.
Chronotherapy, hypoxia-sensitive CAR-T, DLL3/CD3 engagers, ctDNA dynamics —it’s a masterclass in translational innovation.
Let’s keep the convo going: Which abstract are YOU watching most closely?”
Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared Aakash Desai’s post, adding:
“ASCO25 lung cancer updates loading… stay tuned!!”
More posts featuring Aakash Desai.
